IGM Biosciences will stop working in cancer and shrink its T cell engager pipeline to focus on autoimmune diseases, the ...

A New York federal judge dismissed allegations on Monday that Bristol Myers Squibb purposely delayed Breyanzi’s approval to ...

A court ruling Friday will open the door to the FDA more tightly regulating stem cell clinics and a commonly-used stem cell ...

As the potential end of Robert Califf's time as FDA commissioner nears, he and a key deputy are continuing to push forward ...

California Gov. Gavin Newsom vetoed bipartisan legislation on Saturday that would have reformed pharmacy benefit managers in ...

Johnson & Johnson has called off plans to implement a new rebate model for 340B drug price discounts following threats from ...

Ge­nom­ic med­i­cines start­up En­so­ma is shut­ter­ing its Copen­hagen site and al­so elim­i­nat­ing “a very small num­ber” ...

Pfizer will continue shrinking its ownership in the British consumer health company Haleon, according to an announcement ...

Poseida Therapeutics said that 21 of 23 patients (91%) responded to the allogeneic CAR-T therapy it’s developing with Roche ...

Kezar Life Sciences is suspending enrollment and dosing in a lupus trial after four patients died in the mid-stage study of ...

Roche is spending $850 million upfront to buy Regor Pharmaceuticals’ suite of next-generation CDK inhibitors as it doubles ...

As other young radiopharmaceutical companies get acquired by drugmakers, Boston-based Aktis Oncology wants to become one of ...